XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 258.4 $ 117.0
Marketable investment securities 81.4 33.7
Trade accounts receivable 91.3 89.5
Inventory 15.3 27.1
Prepaid taxes 18.4 108.4
Prepaid expenses and other current assets 20.0 13.7
Total current assets 484.8 389.4
Operating lease right-of-use assets 81.8 59.7
Long-term marketable investment securities 59.0 21.0
Property, plant and equipment, net 43.5 40.7
Intangibles, net 404.1 576.5
Goodwill 239.2 329.2
Other assets 8.3 2.3
Total assets 1,320.7 1,418.8
Current liabilities:    
Accounts payable 29.6 20.5
Accrued liabilities 156.5 79.1
Current maturities of operating lease liabilities 13.0 13.6
Deferred revenue 5.2 32.7
Total current liabilities 204.3 145.9
Unrecognized tax benefits 27.9 30.5
Long-term deferred taxes 35.8 71.3
Long-term debt 0.0 224.8
Noncurrent operating lease liabilities 79.3 50.6
Other long-term liabilities 5.6 14.7
Total liabilities 352.9 537.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, $0.01 par value, 80.0 and 75.4 shares outstanding at December 31, 2021 and 2020, respectively 0.8 0.8
Additional paid-in capital 1,226.3 1,109.5
Accumulated other comprehensive loss (5.1) (2.3)
Accumulated deficit (254.2) (227.0)
Total Myriad Genetics, Inc. stockholders' equity 967.8 881.0
Non-controlling interest 0.0 0.0
Total stockholders' equity 967.8 881.0
Total liabilities and stockholders’ equity $ 1,320.7 $ 1,418.8